|
The EESCN Steering Group, which meets three times annually, is the Network's advisory council. Its members provide the very highest level of expertise in the field of stem cells and regenerative medicine across a wide range of interests. The Group, which meets three times annually, ensures that the network represents the interests of EESCN's constituencies, is attuned to developments in the field and can act effectively in fostering the development of new regenerative medicine enterprises. Members
Dr Mary Archer, Chairman, Cambridge University Hospitals NHS Foundation Trust
Dr Archer has been Chairman of Cambridge University Hospital NHS Foundation Trust (Addenbrooke’s Hospital) since 2002; prior to that she was Vice Chairman. Mary chairs the National Urology Informed Decision-Making Project. She taught chemistry in the University of Cambridge for ten years (1976-1986) before developing a wider portfolio of interests in business and public life.
Mr Nigel Atkinson
Nigel was diagnosed with MS about ten years ago. He worked at Cambridge University Press until early 2004 where he was on the Executive Board. Since then he has done some work from home for the Press and has recently started a Part Time Masters at Cambridge University in an area of his personal interest - Social Enterprise and Community Development. As well as being a 'patient trustee of the East of England Stem Cell Network, he is also a Buddy for the MS Society working with the team at the Cambridge Centre for Myelin Repair at Cambridge University.
Dr Chris Bravery, Director of Regulatory Affairs, Advanced Therapy Medicinal Products, ERA Consulting
Dr Bravery has over 10 years of experience in Biotech R&D and regulatory affairs, primarily within the area of Advanced Therapies. He is an former MHRA pharmaceutical assessor with broad experience of biological medicinal products including blood products, recombinant proteins, antibodies, cell therapies, stem cells, tissue engineered products and gene therapies. His assessor experience spans the whole product life cycle of both National and Centralised Procedures - clinical trials assessment (IMPD), new market authorisations (MAA) including 2 biosimilar products, variations (type IB, 2, and line extensions) as well as Scientific Advice Procedures. He is a Member of the Tissue Engineering Steering Group and RGM/1 group of British Standards Institute (BSI) and a Member of Biologicals Working Party of TOPRA. Chris is regularly invited to speak at conferences and workshops on the development and regulation of Advanced Therapy Medicinal Products. Dr Ruth McKernan, Chief Scientific Officer, Pfizer Regenerative Medicine Ruth graduated from the University of London with a first in biochemistry and pharmacology. She gained her PhD at London's Institute of Psychiatry studying the mechanism of action of antidepressant drugs. A Fulbright Scholarship took her to the University of California in San Diego for two years and thereafter Ruth joined the pharmaceutical Industry. In her 20 years' experience she has held many posts including Head of the Merck Neuroscience Research Centre in the UK where she led a group of 250 scientists with a portfolio from idea to POC. Since joining Pfizer three years ago, she has been Vice President of Biology in Sandwich, Head of the Research Technology Centre in Boston and Vice President for External Research in Europe. Most recently, Ruth has been a leader in Pfizer's commitment to emerging therapeutic opportunities and is now Chief Scientific Officer of the newly- formed Regenerative Medicine Unit with research groups in both the UK and US. Scientifically, Ruth is best known for her neuroscience research on ligand-gated ion channels. She is the author of over 120 publications and 15 patents and is a visiting Professor at King's College, London. Her first book for non-scientists, "Billy’s Halo," was short-listed for the 2007 MIND awards. Dr Andrea Kells, Major Projects Manager in the School of Biological Sciences at Cambridge University
Andrea has specific responsibility for developing and supporting external research partnerships and research translation across the biological sciences. Such partnerships at the University of Cambridge are many and diverse, ranging from one-off tightly-defined research projects to large scale framework agreements encompassing a number of parallel projects and multiple research personnel. In addition to University academics, these often also include staff from other affiliated research institutes around Cambridge, and clinical staff working at the 1,000 bed Cambridge University Hospital (Addenbrooke’s). Andrea took up her current position in November 2008. Prior to this she worked for the Research Services Division in the University, as Partnership Development Manager supporting academic collaborations and new strategic research initiatives in the life sciences. She also spent five years working for a science and technology consultancy, where she specialised in evaluations of university-company partnership mechanisms for a range of public and private sector clients, including national Governments. Andrea holds a first degree in Zoology from the University of Cambridge, a Masters degree in applied biosciences from the University of Oxford, and a PhD in animal behaviour from the University of Southampton. Professor Glyn Stacey Professor Stacey is Director of the UK Stem Cell Bank and Head of the Division of Cell Biology and Imaging at the National Institute for Biological Standards and Control (NIBSC). Professor Roger Pedersen, Department of Surgery, University of Cambridge Roger A. Pedersen received degrees in biology from Stanford (A.B, 1965) and Yale (PhD, 1970) and did postdoctoral work at Johns Hopkins. In 1971, he joined the University of California, San Francisco, where he studied developmental potency and fate in mammalian embryos. In 2001 he moved to the University of Cambridge, where he continues his research on human embryonic stem cells as Professor of Regenerative Medicine. From September 2008, Professor Pedersen will also be Director of The Laboratory for Regenerative Medicine, the translational phase of the Cambridge Stem Cell Initiative. Professor Brian Salter, Professor of Politics of Biomedicine and Director of the Global Biopolitics Research Group in the Centre for Biomedicine and Society at King’s College London A political scientist specialising in the analysis of public policy, he has studied the political forces at work in the policy arenas of education, health and, most recently, the life sciences. Here his work focuses on the global politics of new health technologies and the international governance issues surrounding the bioethics and regulatory policies of stem cell research and regenerative medicine. Currently he is particularly interested in the governance challenges raised by the emergence of China and India as significant players in regenerative medicine. He has published nine books and numerous articles including The global politics of human embryonic stem cell science (2008), The new politics of medicine (2004) and The politics of change in the Health Service (1998). Closely associated with his academic work is his role as policy adviser to government, funding agencies, professional and international bodies and his contribution as ethical adviser to the European Framework Programmes. An experienced flight instructor and flight examiner, he is probably the only professor in the UK to have flown a World War II Spitfire.
Professor Suzanne Watt, National Head of Stem Cells and Immunotherapies (SCI) for NHS Blood and Transplant, Director of the NHS Cord Blood Bank, Professor of Haematology, University of Oxford
Suzanne has 28 years' experience in the haematopoietic stem cell/haematopoietic progenitor cell (HSC/HPC) field. She has a PhD degree and was a research associate at the Walter and Elisa Hall Institute in Melbourne Australia. From 2001 Suzanne has been Consultant Clinical Director, National Head of Stem Cells and Immunotherapies within the NHS Blood and Transplant (formerly the National Blood Service) with responsibility for i) the collection, processing, banking and provision of haematopoietic stem cells from bone marrow, peripheral blood and cord blood for transplantation at 9 sites - the SCI processing and banking facilities at Oxford, Cambridge, Bristol (Filton), Leeds, Sheffield, Manchester, Southampton, Birmingham and the NHS Cord Blood Bank (formerly the London Cord Blood Bank) at Edgware and its collection centres ensuring HTA, MHRA, JACIE, FACT licensing/accreditation as relevant; ii) for translational research/clinical trials into haematopoietic stem cells and immunotherapies at appropriate sites; and iii) the stem cell research laboratory in Oxford with cord blood collection site for research into haematopoietic, endothelial and mesenchymal stem cells. Currently, participant in E.U. shared action framework programmes VI and VII, and in former E.U. concerted and shared actions since 1987. Previously co-ordinator of E.U. concerted actions in Western, Central and Eastern Europe. All these relate to stem cells in haematopoietic tissues. Currently membership of committees include: member of the management advisory team of the UK Stem Cell Bank, member of the Steering Committee of the East of England Stem Cell Network and member of the American Society of Haematology. Over 100 publications in the stem cell and haematopoiesis fields.
|
